This site is intended for healthcare professionals

FDA approves label extension for Ozempic for reduction of risk of major adverse cardiovascular events in type 2 diabetes.- Novo Nordisk

Read time: 1 mins
Published:18th Jan 2020
Novo Nordisk has announced that the FDA has approved a label expansion based on a supplemental New Drug Application (sNDA) for Ozempic (once-weekly semaglutide) for the indication of reducing the risk of major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes and established cardiovascular disease (CVD). The approval is based on the SUSTAIN 6 cardiovascular outcomes trial (CVOT), which demonstrated that Ozempic statistically significantly reduced the risk of CV death, non-fatal heart attack or non-fatal stroke by 26% versus placebo, when added to standard of care in people with type 2 diabetes with increased CV risk.
Condition: Diabetes Type 2 + CV Disease
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights